Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash DealGlobeNewsWire • 01/22/24
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers SymposiumGlobeNewsWire • 01/18/24
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)PRNewsWire • 01/04/24
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Coherus BioSciences shares take off on FDA approval of drug delivery deviceProactive Investors • 12/27/23
2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.Market Watch • 12/27/23
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvGlobeNewsWire • 12/26/23
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall StreetThe Motley Fool • 12/24/23
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the NasopharynxGlobeNewsWire • 12/11/23
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology CongressGlobeNewsWire • 12/06/23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 11/06/23
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 11/03/23
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023GlobeNewsWire • 10/30/23
Intuitive Machines stock climbs on lunar mission plan as McDonald's edges higher ahead of resultsMarket Watch • 10/30/23